Eli Lilly’s oral GLP‑1 weight‑loss pill orforglipron receives first approval in China
China’s medicine regulator approved Eli Lilly’s oral GLP‑1 obesity treatment, orforglipron, on 12 November 2026, making it the first oral GLP‑1 pill cleared in the country. The clearance gives Lilly a first‑mover advantage over rivals such as Novo Nordisk, Pfizer and Innovent Biologics. Shares rose 2.38% to $1,472.00 in pre‑market trading following the announcement.
Why it matters
The approval opens a large, fast‑growing Chinese weight‑management market to Lilly’s pill, which could add to revenue growth as the company expands beyond injectables. Analysts note the market could be worth billions of dollars, so investors will watch sales rollout and pricing negotiations.
Key facts
- 1China’s medicine regulator approved orforglipron on 12 November 2026, the first oral GLP‑1 weight‑loss pill cleared in the country. financial-news.co.uk
- 2Lilly shares rose 2.38% to $1,472.00 in pre‑market trading after the approval. financial-news.co.uk
- 3Third‑quarter 2026 revenue was $24.397 billion, up 40% year‑on‑year. financial-news.co.uk
- 4J.P. Morgan estimates China’s GLP‑1 weight‑management market could reach $45 billion within five to seven years. nai500.com
- 5J.P. Morgan also estimates the market could reach RMB 30 billion (approximately $4.5 billion) over the same horizon. finance.yahoo.com
Open questions
- Two J.P. Morgan estimates of the future Chinese GLP‑1 market differ: $45 billion versus $4.5 billion, indicating a conflict in projected size.
Summary written by AlphAI AI Desk from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.